Novartis
Novartis announce digital collaboration with HPE
June 24, 2021AI, HPE, Novartis
Swiss pharma company, Novartis, has announced a collaboration with Hewlett Packard Enterprise (HPE), to accelerate its use of data and …
NICE recommends two new treatments for inflammatory arthritis
June 18, 2021Medical Communications Eli Lilly, NICE, Novartis
NICE has recommended two new treatments for axial spondyloarthritis, an underdiagnosed and debilitating type of inflammatory arthritis. Ixekizumab (also known …
Novartis report longest median OS in breast cancer study
June 3, 2021Novartis, breast cancer, trials
Novartis has announced updated median overall survival (OS) results for Kisqali (ribociclib), in combination with fulvestrant, in postmenopausal women with …
Novartis eye treatment for diabetics shows positive results in Phase III trial
May 4, 2021Manufacturing and Production DME, Novartis, diabetic macular edema, macular edema, pharma, pharma news
Novartis’ Beovu treatment for diabetic macular edema (DME) – an eye condition that can cause blindness – has shown positive …
Novartis multiple sclerosis treatment recommended by NICE
April 20, 2021Manufacturing and Production NICE, Novartis, multiple sclerosis, pharma, pharma news
NICE have recommenced Novartis’ ofatumumab (Kesimpta) for the treatment of relapsing remitting MS (RRMS) in adult patients for use on …
Novartis signs capacity and technology transfer agreement for Roche drug
April 15, 2021Novartis, Roche, production
Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of …
Novartis MS therapy gains MHRA and EC approval
April 8, 2021European Commission, MHRA, Novartis, pharma, pharma news
The MHRA and European Commission have both granted marketing authorisation to Novartis for its Kesimpta therapy, for the treatment of …
Novartis and Artios Pharma to collaborate on DDR cancer therapies
April 7, 2021Research and Development Novartis, RLT, oncology
Novartis and Artios Pharma have announced a global research collaboration to discover and validate next generation DNA damage response (DDR) …
Novartis prostate cancer treatment sees positive Phase III results
March 23, 2021Manufacturing and Production Novartis, oncology
Novartis has today announced positive results from its Phase III VISION study with 177Lu-PSMA-617, seeing significant improvements in overall survival …
Novartis’ canakinumab fails to improve lung cancer survival in Phase III study
March 9, 2021Manufacturing and Production Cancer, Novartis, lung cancer
Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …
Novartis signs agreement to manufacture CureVac’s COVID-19 vaccine
March 5, 2021Medical Communications COVID-19, CureVac, Novartis, vaccines
CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the …
Verona Pharma appoints Novartis Gene Therapies VP Lisa Deschamps to its board
March 2, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, verona, verona pharma
Verona Pharma has appointed Lisa Deschamps, Senior Vice President and Chief Business Officer of Novartis Gene Therapies, as Non-Executive Director …
NICE recommends Novartis’ ribociclib in combination with fulvestrant for breast cancer
February 26, 2021Medical Communications Cancer, NICE, Novartis
NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …
Novartis and Gates Foundation join forces on sickle cell disease research
February 17, 2021Research and Development Novartis, sickle cell disease
Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation, under which the foundation will fund …
FDA approves Novartis’ heart failure drug Entresto
February 17, 2021Research and Development FDA, Novartis
The FDA has approved Novartis’ Entresto (sacubitril/valsartan) to reduce the risk of cardiovascular death and hospitalisation for heart failure in …
